[Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Guérin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)].. Données comparatives moléculaires, précliniques et cliniques des différentes souches de bacille de Calmette-Guérin (BCG) : revue de la littérature du Comité de cancérologie de l’Association française d’urologie (CCAFU)

Archive ouverte

Neuzillet, Y. | Dubosq, F. | Xylinas, E. | Colin, P. | Comperat, E. | Houédé, N. | Larre, S. | Masson-Lecomte, A. | Pignot, G. | Puech, Pascal | Roumiguié, M. | Mejean, A. | Roupret, M.

Edité par CCSD ; Elsevier Masson -

International audience. OBJECTIVE:To review the differences between the BCG strains used for the treatment of non-muscle invasive bladder cancer (NMIBC) at the molecular level, regarding cytotoxicity, immunogenicity, clinical efficiency, and safety.MATERIAL AND METHOD:A systematic review of the literature search was performed from the database MedLine, focused on the following keywords: BCG; bladder; strain; genome; cytotoxicity; immune response; efficiency; safety.RESULTS:Genetic differences between BCG strains have been identified and correlated to their time to differentiation from their initial cultures start, assuming a lower resistance to the host immune defenses of Tice and Danish strains compared to the Connaught strain. Preclinical comparative data showed superior cytotoxic effect and immunogenicity of the Connaught strain compared to Tice and Danish strains. The phase III trials have shown superior efficiency of BCG Connaught compared to BCG Tice and BCG Danish compared to BCG Tice regarding recurrence-free survival.CONCLUSIONS:Among BCG strains used in France in NMIBC treatment, preclinical and clinical efficiency of Connaught strain was higher than that of the Tice strain. The limits of the currently available studies lie primarily in the lack of use of maintenance therapy.

Consulter en ligne

Suggestions

Du même auteur

[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].. Enquête observationnelle du Comité de cancérologie de l’association française d’urologie (CCAFU) sur la pratique des instillations postopératoires précoces (IPOP) de mitomycine C pour le traitement des tumeurs de vessie n’infiltrant pas le muscle (TVNIM)

Archive ouverte | Neuzillet, Y. | CCSD

International audience. OBJECTIVE:To evaluate the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment by urologists members of the Frenc...

[CCAFU french national guidelines 2016-2018 on upper tract tumors].. Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la voie excrétrice supérieure

Archive ouverte | Rouprêt, M. | CCSD

International audience. The purpose was to propose an update of the french guidelines from the national committee CCAFU on upper tract urothelial carcinomas (UTUC).

[CCAFU french national guidelines 2016-2018 on bladder cancer].

Archive ouverte | Rouprêt, M. | CCSD

International audience. OBJECTIVE:The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers...

Chargement des enrichissements...